GLP-1 for Weight Loss and Diabetes
US$ 25.90
glp 1 abbreviation medical Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society GLP-1 Medications – Community Education
Description
In one study, microdosing GLP-1s supported moderate weight loss of up to 10 pounds over 40 weeks in participants. MICRODOSING GLP-1 BENEFITS Do More, Age Less Modulated inflammatory pathways in clinical trials. Studies found a reduced risk of cognitive decline Supported cardiovascular health in clinical trials Improved mitochondrial function and oxidative stress in clinical trials Low doses reduced side effects in clinical trials Supported moderate weight loss of up to 10 pounds over 40 weeks in one study *See studies cited below
JCI Insight 2020;5:e133429.ArticlePubMedPMC 60
The significant burden of CKD and CVD in type 1 diabetes populations highlights the need to identify novel therapies with the potential for heart and kidney protection
Your health journey benefits from an approach that addresses multiple wellness aspects simultaneously
Other GLP-1 drugs can do the trick
3,5 Regulatory considerations play a crucial role in the adoption of GLP-1RAs for addiction treatment
